# Etomidate Versus Propofol in CABG Surgery

Study · id `cardio:ct-nct06068764` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06068764](<https://clinicaltrials.gov/study/NCT06068764>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06068764

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06068764. Randomized; single masking; primary purpose supportive care. Start 2023-12-05 (actual); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06068764, source copy `cardio:ctgov-nct06068764-2023-12-28`, retrieved 2026-10-26)
- Started: 2023-12-05 (actual) (ClinicalTrials.gov record NCT06068764, source copy `cardio:ctgov-nct06068764-2023-12-28`, retrieved 2026-10-26)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06068764, source copy `cardio:ctgov-nct06068764-2023-12-28`, retrieved 2026-10-26)
- Completion: 2026-08 (anticipated) (ClinicalTrials.gov record NCT06068764, source copy `cardio:ctgov-nct06068764-2023-12-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06068764, source copy `cardio:ctgov-nct06068764-2023-12-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06068764-2023-12-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Etomidate Versus Propofol in CABG Surgery
- Acronym: ETOPRO
- Condition: Coronary Artery Disease
- Intervention (Drug): Etomidate
- Intervention (Drug): Propofol
- Lead sponsor: Hartford Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Hartford Hospital (`cardio:org-hartford-hospital`)

## Provenance

Content hash: e3eb981ff033cfa8d04d71a60581db85444160fb43ce7e0c9bb866c4b244be76
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
